Crinetics Pharmaceuticals

Crinetics Pharmaceuticals is a pharmaceutical development company that focuses on the research and creation of therapeutic agents. The firm is incorporated in the United States and maintains its headquarters in San Diego, California. As a Nasdaq‑listed entity, it is subject to the reporting and governance requirements of a public market. Its primary activity involves advancing drug candidates through preclinical and clinical stages toward potential regulatory approval. The company operates within the broader biopharmaceutical sector, targeting diseases where unmet medical need exists.

Being publicly traded on Nasdaq provides Crinetics Pharmaceuticals with access to capital markets and subjects it to shareholder oversight. The organization’s San Diego location situates it within a notable biotech cluster that includes research institutions and other life‑science firms. In early March 2024 the company disclosed a cybersecurity incident involving suspicious activity in an employee account, which prompted an immediate response and third‑party forensic engagement. Although the LockBit ransomware group claimed responsibility, the firm stated that the incident was contained without operational or database impact. These events highlight the company’s need to maintain robust information security protections alongside its drug development efforts.